Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Diagnostics Firm Rents Lab to Neighbor Hemax Genome

MONTREAL, Jan. 17 - Canadian molecular diagnostic company Pro-DNA Diagnostic has agreed to lease its laboratory to Hemax Genome, which will use the facility to bolster its project to map the X chromosome, the firms said on Thursday.

"This agreement represents an ideal opportunity for Hemax since it gives us quick access to the infrastructures and resources we need to ensure the fast expansion of our various R&D mapping programs,'' Marc Lussier, vice-president of HemaX, said in a statement.

Meanwhile, Lambert Busque, Pro-DNA's medical and scientific director, said his firm is reserving the right to use Hemax' technology in the future to help it develop its own gene-mapping expertise.

Financial details of the agreement were not disclosed.

Pro-DNA, founded in 1995 by a group of haematologists and researchers at a Montreal hospital, published the first Canadian studies on the genetic markers of the region's French-Canadian population in 1997.

Hemax specializes in identifying genes located on the human X chromosome. The company is currently engaged in the discovery and therapeutic applications of biological factors that regulate hematopoiesis in stem cells.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.